Why AstraZeneca's Potential Vaccine Is More Exciting Than You Think

In the last three weeks, the world has let out a collective sigh of relief on positive news from coronavirus vaccine trials reported by Pfizer (NYSE:PFE) and partner BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), and AstraZeneca (NASDAQ:AZN). But while the market cheered more than 90% efficacy of the first two vaccine candidates, the results from AstraZeneca's clinical trials were met with more of a shrug. Despite the market's reaction, I think investors have more to be excited about from the potential AstraZeneca vaccine than its efficacy data suggests.